InVitae Corp (NYSE:NVTA) – Investment analysts at Leerink Swann issued their Q1 2019 earnings estimates for InVitae in a research note issued to investors on Tuesday, according to Zacks Investment Research. Leerink Swann analyst P. Souda forecasts that the medical research company will earn ($0.41) per share for the quarter. Leerink Swann has a “Outperform” rating and a $10.00 price objective on the stock. Leerink Swann also issued estimates for InVitae’s Q2 2019 earnings at ($0.38) EPS, Q3 2019 earnings at ($0.33) EPS and Q4 2019 earnings at ($0.21) EPS.
Several other research analysts have also commented on NVTA. Zacks Investment Research lowered shares of InVitae from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 17th. BidaskClub lowered shares of InVitae from a “buy” rating to a “hold” rating in a report on Thursday, October 26th. Ladenburg Thalmann Financial Services initiated coverage on shares of InVitae in a report on Friday, January 5th. They issued a “buy” rating and a $15.00 price target for the company. Benchmark decreased their price target on shares of InVitae from $16.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 16th. Finally, ValuEngine lowered shares of InVitae from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Three research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. InVitae currently has an average rating of “Hold” and an average price target of $12.40.
A number of institutional investors have recently bought and sold shares of NVTA. Teacher Retirement System of Texas acquired a new position in InVitae during the 4th quarter valued at about $116,000. Lakeview Capital Partners LLC acquired a new position in InVitae during the 3rd quarter valued at about $117,000. Gabelli Funds LLC acquired a new position in InVitae during the 3rd quarter valued at about $131,000. State Board of Administration of Florida Retirement System acquired a new position in InVitae during the 3rd quarter valued at about $133,000. Finally, CAPROCK Group Inc. acquired a new position in InVitae during the 3rd quarter valued at about $139,000. 64.89% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/11/invitae-corp-nvta-expected-to-earn-q1-2019-earnings-of-0-41-per-share.html.
InVitae Company Profile
Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for InVitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae and related companies with MarketBeat.com's FREE daily email newsletter.